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Abstract
Hematopoietic cell transplantation (HCT) is an established procedure for acquired and congenital disorders of the
hematopoietic system. In 2016, there was a tendency for continued activity in this ﬁeld with 43,636 HCT in 39,313 patients
[16,507 allogeneic (42%), 22,806 autologous (58%)] reported by 679 centers in 49 countries in 2016. The main indications
were myeloid malignancies 9547 (24%; 96% allogeneic), lymphoid malignancies 25,618 (65%; 20% allogeneic), solid tumors
1516 (4%; 2% allogeneic), and non-malignant disorders 2459 (6%; 85% allogeneic). There was a remarkable leveling off in
the use of unrelated donor HCT being replaced by haploidentical HCT. Continued growth in allogeneic HCT for marrow
failure, AML, and MPN was seen, whereas MDS appears stable. Allogeneic HCT for lymphoid malignancies vary in trend
with increases for NHL and decreases for Hodgkin lymphoma and myeloma. Trends in CLL are not clear, with recent
increases after a decrease in activity. In autologous HCT, the use in myeloma continues to expand but is stable in Hodgkin
lymphoma. There is a notable increase in autologous HCT for autoimmune disease. These data reﬂect the most recent
advances in the ﬁeld, in which some trends and changes are likely to be related to development of non-transplant technologies.
Introduction
Hematopoietic cell transplantation (HCT) is an established
procedure for many disorders of the hematopoietic system
including those of the immune system, and as enzyme
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replacement in metabolic disorders [1–4]. The activity
survey of the European Society of Blood and Marrow
Transplantation (EBMT), describing the status of HCT in
Europe and afﬁliated countries, has become an instrument
to observe trends and to monitor changes in technology [5–
13]. The survey using a standardized structure captures the
numbers of HCT from highly committed participating
teams, divided by indication, donor type, and stem cell
source. More recently, the survey has included information
on novel cell therapies with hematopoietic stem cells for
non-hematopoietic use, and the use of non-hematopoietic
stem and progenitor cells. This coincides with the interest of
the World Health Organization WHO (www.who.org) in
cell and tissue transplants and further stresses the need for
adequate and timely information [14]. The analysis of the
survey data spanning 26 years and amassing data on more
than 660,000 transplants in over 580,000 patients has
shown a continued and constant increase in the annual
numbers of HCT and transplant rates for both allogeneic
and autologous HCT.
This report is based on the 2016 survey data. In addition
to transplant rates and indications, it focuses on the use of
haploidentical donors for transplantation, including disease
entities and stem cell source.
Patients and methods
Data collection and validation
Participating teams were invited to report data for 2016 as
listed in Table 1. The survey allows the possibility to report
additional information on the numbers of subsequent
transplants performed as a result of relapse, rejection or
those that are part of a planned sequential transplant
protocol.
Supplementary information on the numbers of donor
lymphocyte infusions, reduced intensity HCT and the
numbers of pediatric HCT is also collected. Quality control
measures included several independent systems: conﬁrma-
tion of validity of the entered data by the reporting team,
selective comparison of the survey data with MED-A data
sets in the EBMT Registry database and cross-checking
with the National Registries.
Teams
A total of 707 centers from 49 countries were contacted
for the 2016 survey (40 European and 9 afﬁliated coun-
tries); of which 679 teams reported. This corresponds to a
96% return rate and includes 577 active EBMT member
teams. Twenty-eight active teams failed to report in 2016.
Contacted teams are listed in the online appendix in
alphabetical order by country, city and EBMT center code,
with their reported numbers of ﬁrst and total HCT, and of
ﬁrst allogeneic and autologous HCT as supplementary
material. The WHO regional ofﬁce deﬁnitions were used to
classify countries as European or Non-European. Eight non-
European countries participated in the 2016 EBMT survey:
Algeria, Iran, Israel, Jordan, Lebanon, Saudi Arabia, South
Africa and Tunisia. Their data (2795 HCT in 2659 patients)
from 32 actively transplanting teams make up 6.4% of the
total data set and are included in all analyses [14].
Patient and transplant numbers
Wherever appropriate, patient numbers corresponding to the
number of patients receiving a ﬁrst transplant, and trans-
plant numbers reﬂecting the total number of transplants
performed are listed.
The term sibling donor includes HLA identical siblings
and twins but not siblings with HLA mismatches. Unrelated
donor transplants include HCT from matched or mis-
matched unrelated donors with peripheral blood and mar-
row as a stem cell source but not cord blood HCT. In the
2016 survey we collected separately the numbers of haplo-
identical and other family member HCT. Haplo-identical
transplants are being described as any family member with
2 or more loci mismatch within the loci HLA-A, -B, -C,
-DRB1, and -DQB1 in GvH and/or HvG direction. Other
family member donors are those related donors that are
mismatched to a lesser degree than a full haplotype. Addi-
tional non ﬁrst transplants may include multiple transplants
deﬁned as subsequent transplants within a planned double
or triple autologous or allogeneic HCT protocol, and
retransplants (autologous or allogeneic) deﬁned as unplan-
ned HCT for rejection or relapse after a previous HCT.
Transplant rates
Transplant rates, deﬁned as the total number of HCT per 10
million inhabitants, were computed for each country with-
out adjustments for patients who crossed borders and
received their HCT in a foreign country. Population num-
bers for 2016 were obtained from Eurostats for the Eur-
opean countries (http://epp.eurostat.ec.europa.eu/portal/pa
ge/portal/statistics/search_database) and the US census
bureau database for the non-European countries
(http://www.census.gov/population/international/data/idb/ra
nk.php).
Analysis
Wherever appropriate, the absolute numbers of transplanted
patients, transplants or transplant rates are shown for
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Table 1 Numbers of HCT in Europe 2016 by indication, donor type, and stem cell source
Transplant activity 2016
No. of patients
Allogeneic Autologous Total
Family Unrelated
HLA-id Twin Haplo≥2MM Other family BM BM+ Allo Auto Total
BM PBPC Cord all BM PBSC BM PBPC Cord BM PBPC Cord only PBPC Cord
Myeloid malignancies 396 2533 2 8 354 757 17 83 2 474 4408 156 8 349 9190 357 9547
Acute myeloid leukemia 272 1825 1 5 256 569 13 70 2 302 2849 117 8 346 6281 354 6635
1st complete remission 185 1166 5 122 253 5 39 2 183 1535 72 6 289 3567 295 3862
Not 1st complete remission 68 438 1 100 233 7 25 83 792 33 2 52 1780 54 1834
AML therapy related 3 62 9 37 2 13 135 7 3 268 3 271
AML from MDS/MPN 16 159 25 46 1 4 23 387 5 2 666 2 668
Chronic myeloid leukemia 32 102 1 15 24 1 4 25 174 6 1 384 1 385
Chronic phase 13 51 1 2 9 1 4 15 75 2 1 173 1 174
Not chronic phase 19 51 13 15 10 99 4 211 0 211
MDS or MD/MPN overlap 86 419 2 56 130 2 8 131 1014 30 2 1878 2 1880
MPN 6 187 1 27 34 1 1 16 3 647 0 647
Lymphoid malignancies 334 1495 6 11 192 462 15 56 1 414 1956 95 33 20,548 5037 20,581 25,618
Acute lymphatic leukemia 263 734 6 3 96 237 12 33 1 333 859 74 5 85 2651 90 2741
1st complete remission 158 537 2 2 47 95 6 21 185 551 34 4 76 1638 80 1718
not 1st complete remission 105 197 4 1 49 142 6 12 1 148 308 40 1 9 1013 10 1023
Chronic lymphocytic leukemia 5 92 7 14 1 1 8 144 3 17 275 17 292
Plasma cell disorders—MM 5 145 2 13 13 1 14 240 2 11,549 433 11,551 11,984
Plasma cell disorders—other 2 12 1 1 14 380 30 380 410
Hodgkin lymphoma 17 134 1 37 74 2 9 112 4 14 2031 390 2045 2435
Non Hodgkin lymphoma 42 378 5 39 123 2 19 49 587 14 12 6486 1258 6498 7756
Solid tumors 3 23 1 6 42 1440 1 33 1483 1516
Neuroblastoma 1 16 1 2 20 459 20 479 499
Soft tissue sarcoma/Ewing 1 4 1 4 186 6 190 196
Germinal tumors 1 1 398 1 399 400
Breast cancer 21 0 21 21
Other solid tumors 3 3 17 376 1 6 394 400
Non malignant disorders 640 245 28 1 67 149 80 50 454 283 90 8 364 2087 372 2459
Bone marrow failure—SAA 193 119 1 1 18 26 9 5 152 107 11 5 642 5 647
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Table 1 (continued)
Transplant activity 2016
No. of patients
Allogeneic Autologous Total
Family Unrelated
HLA-id Twin Haplo≥2MM Other family BM BM+ Allo Auto Total
BM PBPC Cord all BM PBSC BM PBPC Cord BM PBPC Cord only PBPC Cord
Bone marrow failure—other 82 26 6 14 11 10 9 58 27 9 252 0 252
Thalassemia 138 50 15 9 12 21 11 53 19 1 6 329 6 335
Sickle cell disease 78 20 3 6 6 8 2 11 3 1 137 1 138
Primary Immune deﬁciencies 116 27 2 14 79 25 16 134 97 40 2 3 550 5 555
Inh. disorders of Metabolism 28 2 1 5 13 7 6 40 21 27 3 1 150 4 154
Auto immune disease 5 1 1 2 1 6 9 2 2 349 27 351 378
Others 21 15 2 7 18 4 2 1 37 39 14 13 160 13 173
Total patients 1391 4291 38 20 620 1409 116 192 4 1379 6692 355 91 22,714 1 16,507 22,806 39,313
Re/additional transplants 41 212 4 4 73 204 6 22 1 73 459 35 7 3182 1134 3189 4323
Total transplants 1432 4503 42 24 693 1613 122 214 5 1452 7151 390 98 25,896 1 17,641 25,995 43,636
Numbers of HCT in Europe 2016 by indication, donor type and stem cell source.
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speciﬁc countries, indications or transplant techniques.
Myeloid malignancies include acute myeloid leukemia
(AML), myelodysplastic or myelodysplastic/myeloproli-
ferative neoplasm (MDS/MPN), myeloproliferative neo-
plasm (MPN) and chronic myeloid leukemia (CML).
Lymphoid malignancies include acute lymphocytic leuke-
mia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin
lymphoma (HL), non-Hodgkin lymphoma (NHL), and
plasma cell disorders (PCD).The non-malignant disorders
include bone marrow failure (BMF), thalassemia, sickle cell
disease, primary immune disease (PID), inherited disease of
metabolism (IDM) and auto immune disease (AID). Others
include histiocytosis and rare disorders not included in the
above. Trends shown over time include changes in absolute
number of patients transplanted from 1990 to 2016, with
exception to MPN and MDS, where these entities were
grouped until 2004 and for autoimmune disease, where the
ﬁrst treatments were reported in 1997. We use graphical
representation to indicate changes over time. To conﬁrm
trends we used SPSS to automatically ﬁt the best expo-
nentially smoothed, autoregressive integrated moving
average (ARIMA) model without any further pre-
speciﬁcation. To detect possible deviations from trends,
we show the observed and predicted counts as well as the
95% conﬁdence intervals.
Results
Participating teams in 2016
Of the 679 teams, 432 (63%) performed both allogeneic and
autologous transplants; 227 (34%) restricted their activity to
autologous HCT, and 12 (2%) to allogeneic transplants
only. Eight teams (1%) reported having performed no
transplants in 2016 due to renovation or temporary closure
of the transplant unit. Of the 679 active centers, 123 (18%)
centers performed transplants on both adult and pediatric
patients. An additional 112 (16%) centers were dedicated
pediatric transplant centers and 444 (65%) centers per-
formed transplants on adults only. Twenty-eight active
teams failed to report in 2016 which when compared to
previously reported data by these teams accounts for a
possible 496 missing HCT.
Number of patients and transplants
In 2016, a total of 43,636 transplants were reported in
39,313 patients (ﬁrst transplant); of these, 17,641 HCT
(40%) were allogeneic and 25,995 (60%) autologous
(Table 1). When compared with 2015 the total number of
transplants increased by 3.5% (2.0% allogeneic HCT and
4.5% autologous HCT) [12], and the corresponding increase
in numbers comparing 2006 to 2016 are 52% higher (68%
allogeneic and 43% autologous). In patients receiving their
ﬁrst transplant in 2016, the increase was 3.0% for allogeneic
HCT and 5.6% for autologous HCT. Within allogeneic
HCT, the main part of the increase seen concerned pediatric
patients (6.2% increase for pediatric, 2.1% increase for adult
patients). Furthermore, there were 4323 second or sub-
sequent transplants, being 1134 allogeneic, mainly to treat
relapse or graft failure and 3189 autologous, the majority of
which were most likely part of multiple transplant proce-
dures such as either tandem procedures, or as salvage
autologous transplants for plasma cell disorders, for which a
recent randomized trial conﬁrmed survival beneﬁt [15]. In
addition, 839 HCTs were reported as allogeneic HCT after a
previous autologous HCT, and were mainly for lymphoma
or plasma cell disorders. The total number of patients
transplanted under the age of 18 in both dedicated and joint
adult-pediatric units was 4690, an increase of 4.5% when
compared to 2015, (3545 (+6.2%) allogeneic and 1145
(−0.6%) autologous HCT). Of these, 3206 patients (2498
allogeneic and 708 autologous) reporting a total of 3225
transplants were performed in dedicated pediatric centers.
Indications
Indications for HCT in 2016 are listed in detail in Table 1.
The main diseases were myeloid malignancies (AML,
CML, MDS, and MPN): 9547 (24% of total; 96% of which
were allogeneic); lymphoid malignancies (ALL, CLL, HL,
NHL, and PCD): 25,618 (65%; 20% allogeneic); solid
tumors: 1516 (4%; 2% allogeneic); non-malignant dis-
orders: 2459 (6%; 85% allogeneic) and others: 173 (0.4%).
As seen in previous years, the majority of HCT for lym-
phoid malignancies were autologous, while most transplants
for myeloid malignancies were performed using stem cells
from allogeneic donors. Autologous HCT for non-
malignant disorders predominantly include patients with
autoimmune disorders.
Figure 1a, b show as a pie graph the distribution of
disease indications for allogeneic (Fig. 1a) and autologous
(Fig. 1b) HCT. For allogeneic HCT, AML is the most
frequent indication (38%), of these 21% were for patients in
CR1, 11% for patients with more advanced disease and 6%
for patients with transformed AML, either therapy-related
or from MDS/MPN. Compared to 2015, there were
increases in allogeneic HCT for ALL by 6.3%, MPN by
21.4%, and SAA by 13.4%.
Figure 2a shows the increasing use of autologous and
allogeneic HCT over 26 years. In Figure 2b the use of
different donors for allogeneic HCT is shown. For the ﬁrst
time since 1990, the continued increase in use of unrelated
donor HCT appears to be leveling off. Comparing observed
and expected values of unrelated donor HCTs suggests that
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Fig. 1 Relative proportion of disease indications for HCT in Europe in 2016. a Allogeneic HCT. b Autologous HCT
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since 2015 a substantially lower count of unrelated donor
transplants than expected was observed although this
deviance remains just within the 95% conﬁdence limits
using the ARIMA model (see supplementary table 1 and
Figure 1). Matched sibling donor HCT appears to be
increasing slowly, and there is a clear and continued growth
in the use of haploidentical donor HCT. The use of cord
blood transplantation appears to stabilize in numbers after a
decrease from 2010 to 2015 as shown in Figure 2c. Eur-
opean maps depicting transplant rates by country are pro-
vided in the supplementary section (Supplementary
Figure 2a, 2b).
Important trends in 2016
Figure 3 shows speciﬁc trends over time for some indica-
tions highlighted here for special interest. Figure 3a depicts
the use of allogeneic HCT for CML in ﬁrst chronic phase
and more advanced disease. It is of interest to see that, after
the major decrease due to the introduction of tyrosine kinase
inhibitors in 2000 there is a stable number of approximately
400 patients receiving an allogeneic HCT annually between
2008 and 2016. Figure 3b shows the corresponding graphs
for allogeneic HCT for MDS and MPN. The time axis starts
in 2004 as MDS and MPN information was grouped until
this time. It appears that the use of allogeneic HCT is
leveling off in MDS since 2014 whereas for MPN it con-
tinues to increase. Figure 3c shows allogeneic HCT for
marrow failure with continuing increased use over time.
Allogeneic HCT for lymphoid malignancies is shown in
Figure 3d. There is a mixed picture with increasing numbers
for NHL and decreasing numbers for PCD and HL. There is
a slight increase of 8% in use of allogeneic HCT in CLL,
after a major decrease by 49% between the years 2011 and
2015. Trends in autologous HCT are shown in Figure 3e,
where use in PCD shows a continuous increase, less so for
NHL and a leveling off in HL. Figure 3f shows trends in
autologous HCT in AID with a sharp increase in the last 5
years, mostly driven by autologous HCT for multiple
sclerosis in specialized centers. Among allogeneic HCT,
6878 were performed using non myeloablative condition-
ing. This comprises 39% of all allogeneic HCT, and has
remained stable over the last 8 years.
To address the question as to whether sibling, unrelated
and haploidentical HCT were used differently according to
available resources, we looked at the transplant rates over
the last 5 years in the three income groups; very high
(>41,000 USD), high (8200–41,000 USD) and upper mid-
dle income groups (2080–8200 USD) deﬁned as gross
national income in USD per capita according to World
Bank criteria (http://wdi.worldbank.org/table/WV.1).
Table 2 shows that unrelated donor transplant rates vary
greatly by income. Rates of haploidentical HCT were higher
in the high-income group when compared to the very high-
income group. This argues in favor of haploidentical HCT
being used in place of unrelated HCT, possibly based in part
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Fig. 3 Major trends in disease indication in Europe 1990–2016. a
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on economic considerations. In the upper middle income
groups, rates of alternative donor HCT were equally low,
when compared to sibling donor HCT, possibly pointing
toward restricting HCT technology to the best possible
donor in a situation of limited resources [16].
Cellular therapy use
Table 3 shows cellular therapies performed in EBMT cen-
ters in 2016. There were 2879 patients receiving donor
lymphocyte infusions, a similar number to that in the 2015
report (2941). A total of 1153 patients received other forms
of cellular therapy, most commonly mesenchymal stromal
cells (n= 491), mainly to treat graft versus host disease.
The second most common indication was expanded/
selected T lymphocytes to treat infections (n= 157) or
malignancy (n= 35). Only very few (n= 36) cellular
therapies using genetically modiﬁed allogeneic or auto-
logous T-lymphocytes were reported in 2016. Mesenchymal
stromal cells have been used for over a decade now and
continue to increase (supplementary ﬁgure 3) [17–19].
Discussion
The EBMT activity survey has been conducted annually
since 1990 [7]. The 2010 survey reported for the ﬁrst time
more than 30,000 patients transplanted in a given year, and
more than >40,000 transplants in 2014. Once again, trans-
plant numbers continue to increase across Europe.
Of interest, autologous HCT continues to expand (4.5%)
at a higher rate than allogeneic HCT (2.0%) (Fig. 2a). In
allogeneic HCT some indications continue to increase but
not in others. Furthermore, while the use of unrelated
donors is no longer increasing, the use of sibling donors
continues to do so but more slowly than in previous years.
Within haploidentical HCT we see a continued growth. To
analyze whether these, albeit subtle changes, were related to
resource use, we calculated transplant rates according to
wealth of particular countries. The majority of unrelated
donor HCT was done in very high-income countries,
whereas the less wealthy countries used haploidentical HCT
more frequently than unrelated donors as a stem cell source
pointing to some economic impact on donor choices. Of
interest, all of the highest income countries have a national
Table 2 Transplant rates per 10 million inhabitants during the years
2012 and 2016 by donor choice and income group
Transplant rates per 10 million inhabitants
Donor type
Identical Sibling Haploidentical
family
Unrelated
Income group
Very high 390 77 978
High 283 106 321
Upper
middle
102 16 16
Transplant rates per 10 million inhabitants (TR) over the years
2012–2016 by donor choice and income group
Table 3 Non HCT cellular therapies using manipulated cells in 2016
Number of patients DLI MSC NK cells Selected/
expanded
T cells or
CIK
Regulatory
T cells
(TREGS)
Geneti-
cally
modiﬁed
T cells
Dendritic
cells
Expanded
CD34+
cells
Geneti-
cally
modiﬁed
CD34+
cells
Other
Allo Auto Allo Auto Allo Auto Allo Auto Allo Auto Allo Auto Allo Auto Allo Auto Allo Auto
GvHD 421 2 4 31 1 11 36
Graft enhancement 722 17 4 5 20 1 14 1 75 22
Autoimmune dis. 9 19
Genetic disease 1 1 1
Infection 4 157 7
Malignancy 1 9 32 3 28 6 29 3 45 1 8 16 1
DLI for residual
disease
458
DLI for relapse 1329
DLI per protocol 370
Regenerative
medicine
5 8 1 14 79
Total 2879 458 33 14 0 213 3 59 0 7 29 3 45 16 1 1 8 124 139
Numbers of cellular therapies in Europe 2016 by indication, donor type and cell source
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unrelated donor registry when compared to only 36% of the
upper middle income countries. The least wealthy countries
concentrated on sibling donor HCT and used alternative
donors the least. There is also a hint toward stabilization in
the use of cord blood as a stem cell source (Fig. 2c), 34% of
which were for non malignant diseases. We do not have
information on the age of the patients receiving cord blood
as a stem cell source, however 43% were done in dedicated
pediatric centers. As shown in Fig. 2b the phenomenal
growth of unrelated donor HCT between 2004 and 2015,
appears to level off. Annual growth of unrelated donor HCT
was 13% between the years 2006-2010 and only 1.3%
between the years 2014-2016. Future analyses will show
whether this leveling off is a true effect or just due to annual
variation. As the observation spans 3 years, it would indi-
cate otherwise. Obviously, such trends, if conﬁrmed, will be
important for use of medical resources. The success of
unrelated donor HCT is due to the intensive work done by
donor registries, recruiting and providing well matched
donors for many patients. Clearly it is highly speculative to
predict future developments, but it appears as if haploi-
dentical HCT is the main competitor. This has been
recognized by the transplant community, and randomized
clinical trials comparing unrelated donor HCT to haploi-
dentical donor HCT are underway. Results of these trials
will undoubtedly be instrumental to guide future
recommendations.
Among indications for allogeneic HCT, its use in CLL
appears to stabilize or increase, after dropping in the
previous years. The majority of allogeneic HCT continues
to be for myeloid neoplasia, with AML in the lead, with
more frequent use in MPN but no further increase in
MDS. Additional follow-up will show whether these
trends persist. The trend of allogeneic HCT in CML is
interesting; the drop in transplant numbers seen after the
introduction of kinase inhibitors appears now to have left
a stable number of around 400 CML patients being
transplanted in chronic or more advanced phases, most
likely after kinase inhibitor failure [20]. Allogeneic HCT
for lymphoid neoplasia continues to be used variably,
with an increased indication for in ALL and NHL and less
use in HL and PCD. Over 800 patients with marrow
failure are transplanted each year, and the numbers appear
to grow, in spite of alternative treatment being developed.
Continued growth in transplants for marrow failure
includes both acquired and congenital marrow failure in
all donor types and with unrelated and haploidentical
HCT accounting for 466 patients as compared to sibling
donor HCT with 428 patients in 2016, suggesting a slight
preference for alternative donor HCT over sibling donor
HCT.
Autologous HCT has been continuously more indicated
for myeloma, possibly a result of randomized controlled
trials conﬁrming beneﬁt of autologous HCT in the era of
modern therapies [21]. Indications for NHL increase at a
lower rate (7.0%) and appear to stabilize in HL possibly due
to development of monoclonal antibodies and check point
inhibitors for this disease [22]. This pertains to allogeneic
HCT for HL as well. Autologous HCT for autoimmune
disease has seen a major increase, largely due to a number
of centers using this technology to treat multiple sclerosis
[23, 24].
The section on cellular therapies shows the gradual
increasing use of mesenchymal stromal cells, most com-
monly to treat graft versus host disease. There is a growth
in the use of cell therapy use to treat infectious complica-
tions such as CMV or EBV, using selected and/or expan-
ded T-cell products. Of note, only a few genetically
modiﬁed T-cell therapies have been reported. Whereas the
authors are conﬁdent that transplant numbers are reported
correctly by an overwhelming majority of EBMT member
or associated centers, they are less sure about the reporting
on cellular therapies. The currently available data state, that
although many groups work on genetically modiﬁed T-
cells for immunotherapy only a limited number of patients
have been treated so far. As cellular therapies, in particular
CAR-T cells [25] have become commercially available,
and given that cell collections are restricted to centers
experienced and accredited in apheresis [26], it is most
important that EBMT centers continue the well-established
practice of transparently sharing data on activity of cellular
products used and on outcome of patients. The EBMT
registry database collecting data on transplant outcome
since 1973, currently including cellular therapy data, and
accreditation by JACIE are the tools within the EBMT to
assure highest levels of scientiﬁc exchange and assurance
of qualities.
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